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Role of nitric oxide in renal hemodynamic abnormalities of cyclosponn
nephrotoxicity. To evaluate the participation of nitric oxide (NO) in
chronic cyclosporin A (CsA) nephrotoxicity, the glomerular hemodynamic
response to NO inhibition with N-nitro-L-arginine-methyl-ester (NAME)
and stimulation of NO production with L-arginine was studied in unine-
phrectomized rats. Chronic CsA administration produced renal vasocon-
striction, characterized by increased afferent (AR) and efferent (ER)
resistances, decrease of glomerular plasma flow (QA) and ultrafiltration
coefficient (K1) that resulted in a 53% fall of single-nephron glomerular
filtration rate (SNGFR). NAME infusion in vehicle group (V) elevated
mean arterial pressure (MAP), AR and ER, reduced QA and K1, and
increased glomerular capillary pressure (PGC), resulting in a 28.9% fall of
SNGFR. In the CsA group, NAME also increased MAP, but renal
vasoconstriction was more intense; a greater rise of AR lowered GC (P <
0.05 vs. V) further decreasing SNGFR by 38.9%. In control rats, L-
arginine infusion induced a vasodilatoiy response of AR and ER, and
elevation of QA and K1, which resulted in a 72.6% increase in SNGFR. In
the CsA group, greater vasodilation was observed and SNGFR rose by
114.9%. NO2/NO3 urinary excretion was similar in CsA and V groups,
and it was not modified by NAME in either group, but it increased five- to
sixfold during L-arginine infusion in both groups. In conclusion, in CsA
nephrotoxicity NO production seems to be normal and the ability of the
renal endothelium to produce NO is maintained. Therefore renal vaso-
constriction associated with CsA is not mediated by NO deficiency,
although NO appears to attenuate it.
Cyclosporin A (CsA) is an immunosuppressive agent success-
fully used to prevent organ transplant rejection; however, it
frequently induces renal dysfunction [1—4]. The acute toxic effects
on the kidney are characterized by a decrease in glomerular
filtration rate and renal blood flow, which are completely revers-
ible after drug withdrawal, and no structural damage is observed
[41. In contrast, chronic administration of CsA induces tubuloin-
terstitial fibrosis and vascular lesions that result in a progressive
nephropathy [2, 3], Micropuncture studies have demonstrated
marked constriction of the renal microvasculature resulting in
reduced glomerular plasma flow, and single nephron GFR [5—8]
associated to a decrease in the ultrafiltration coefficient [5, 6]. The
mechanisms involved in these alterations have not been com-
pletely elucidated.
It is now recognized that the balance between vasoconstricting
and vasodilating factors regulates blood flow and perfusion pres-
sure in most vascular territories, including the kidney [9, 10].
Endothelin, thromboxane A2, and angiotensin II have been
implicated as the constrictive factors [11—17]. On the other hand,
nitric oxide (NO), a potent vasorelaxing factor produced by the
endothelium, seems to play an important role in these processes.
Accordingly it has been suggested that the vasoconstricting
effect of CsA may result from a loss of balance in the release of
vasoactive factors either by increased production of vasoconstric-
tors or decreased synthesis of vasodilators.
Experimentally it is possible to assess the contribution of NO in
the regulation of blood pressure and kidney function by specific
inhibitors such as N-nitro-L-arginine-methyl-ester (NAME),
which is an analogue of L-arginine, the NO precursor [9].
Administration of L-arginine stimulates NO synthesis, and has
been used to evaluate the ability of the endothelium to produce
nitric oxide [18]. In addition, NO production can be indirectly
evaluated by measuring the stable end products of NO metabo-
lism, N02 and N03
To explore the participation of NO in chronic CsA nephrotox-
icity, the glomerular hemodynamic response and N02/N03
urinary excretion were evaluated after NAME and L-arginine
infusion in uninephrectomized rats which were chronically treated
with CsA.
Methods
Male Wistar rats, weighing between 300 and 350 g, were
subjected to right nephrectomy (UNx) under ether anesthesia.
After 15 days, the animals received daily subcutaneous injections
of either CsA, 30 mg/kg of body weight or vehicle 0.1 ml of olive
oil (V group) during 30 days. Rats receiving vehicle were pair-fed
and used as controls. Micropuncture studies were performed 30
d, ys after CsA or vehicle administration in the following groups of
r :s.
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Renal hemodynamics were measured in four UNx rats treated
with CsA and five UNx rats receiving V. In addition, the basal
period of the other experimental groups was included in the CsA
and V rats and analyzed together to evaluate CsA nephrotoxicity,
making a total of 16 rats receiving CsA and 20 receiving V.
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Effect of the inhibition of NO synthesis
Glomerular hemodynamics were measured before and during
the inhibition of NO synthesis with NAME in six CsA-treated rats
(CsA+NAME group) and six controls (V+NAME group);
NAME was given as a 10 mg/kg i.v. bolus, followed by an infusion
of 50 ig/kg/min. This dose has been proven to be sufficient to
produce systemic and renal NO blockade effects [19].
Effect of the stimulation of NO synthesis
Glomerular hemodynamics were measured before and during
L-arginine infusion (15 mg/kg/mm) in six rats treated with CsA
(CsA+ARG group) and nine controls (V+ARG group). This
dose was chosen because it was the optimal L-arginine concen-
tration to maintain a pH close to physiological ranges and to
produce systemic and renal effects.
Micropuncture studies
For micropuncture studies, rats were anesthetized with sodium
pentobarbital (30 mg/kg, i.p.), and supplemental doses were
instilled as required. The rats were placed on a thermoregulated
table, and temperature was maintained at 37°C. Trachea, both
jugular veins, femoral arteries, and the left ureter were catheter-
ized with polyethylene tubing PE-240, PE-50, and PE-lO, respec-
tively. The left kidney was exposed, placed in a lucite holder and
sealed, covering its surface with Ringer's solution. Mean arterial
pressure was continuously monitored with a pressure transducer
(Model p23 db, Gould, Hato Rey, Puerto Rico) and recorded on
a polygraph (Grass Instruments, Quincy, Massachusetts, USA).
Blood samples were taken periodically and replaced with blood
from a donor rat.
Rats were maintained under euvolemic conditions by infusion
of 10 ml/kg of body weight of isotonic rat plasma during surgery,
followed by an infusion of 5% polyfructosan, 2.2 mI/hr (Inutest,
Laevosan-Gesellschaft, Germany). After 60 minutes, five to six
three-minute collection samples of proximal tubular fluid were
obtained to determine flow rate and polyfructosan concentration.
Intratubular pressure under free flow (FFP) and stop flow (SFP)
conditions, and peritubular capillary pressure (CP) were mea-
sured in other proximal tubules with a servo-null device (Servo
Nulling Pressure System, Instrumentation for Physiology and
Medicine, Inc., San Diego, California, USA) as previously de-
scribed [20]. Polyfructosan was measured in plasma and urine
samples. Glomerular colloid osmotic pressure was estimated in
protein from blood of the femoral artery (CA) and surface efferent
arterioles (Ce).
For NAME and L-arginine infusion experiments, 30 and 45
minute equilibrium periods were allowed after administration of
the compounds before micropuncture measurements were re-
peated.
Analytical determinations
Polyfructosan concentrations were determined according to the
technique described by Davidson and Sackner [21]. Tubular fluid
volume was estimated as previously described [20]. Concentration
of tubular polyfructosan was measured by the method of Vurek
and Pegram [22]. Protein concentration in afferent and efferent
samples was determined according to the method of Viets et al
[23]. Plasma and urinary sodium concentration were determined
by flame photometry (Instruments Laboratory Mod. 943).
Glomerular filtration rate (GFR), single nephron glomerular
filtration rate (SNGFR), calculated glomerular capillary hydro-
static pressure (P0), glomerular capillary hydrostatic pressure
gradient (iW), single nephron filtration fraction (SNFF), single
nephron plasma flow (Q4, single nephron blood flow (SNBF),
afferent (AR) and effercnt (ER) resistances, ultrafiltration coeffi-
cient (I(f), and oncotic pressure (n) were estimated according to
equations given elsewhere [24].
Quantitation of NO2/N03
The stable end products of NO, NO2 and N03 were esti-
mated in the urine samples obtained during micropuncture stud-
ies in five rats of each group, before and after NAME or
L-arginine infusion. The samples from the basal period of the
NAME and L-arginine were analyzed together to evaluate NO2/
NO3 urinary excretion, making a total of 10 CsA and 10 V
animals. Samples were first incubated with E. coli nitrate reduc-
tase to convert the NO3— to NO2—, as described by Bartholomew
[25] and Granger et al [26]. To prepare this enzyme, E. coli were
grown for 18 hour under anaerobic conditions in nitrate rich
medium, washed, resuspended in PBS and frozen at —70°C until
use. The samples were incubated with the enzyme in phosphate-
ammonium formate buffer (pH 7.3) for one hour at 37°C. After
incubation, total N02 in the samples (representing both NO2
and reduced NO3—) was measured using the Griess reagent.
Known concentrations of NaNO2 and NaNO3 were used as
standards in each assay.
After micropuncture, the kidney was perfused with phosphate
buffer and excised; one-half of the kidney was fixed with alcoholic
Bouin solution and processed for light microscopy, whereas the
other half was fixed with 3% glutaraldehyde and processed for
electron microscopy.
Statistical analysis
The results are expressed as mean standard error. Statistical
differences between baseline and experimental conditions were
assessed by paired Student's t-test. Comparison between groups
was made by unpaired Student's t-test. Statistical difference was
defined when P < 0.05.
Results
Cyclosporin nephrotoxicity
The effects of chronic CsA administration in UNx rats on
glomerular microcirculation are summarized in Table 1. Results
obtained in CsA-treated rats are compared with vehicle-treated
animals. Body weight was similar in both groups; however, kidney
weight was 10% lower in CsA-treated rats. Hematocrit was
slightly but significantly lower in CsA treated rats (41.2 1.2 vs.
49.4 1.3 P C 0.005); in both groups it remained constant after
the equilibrium period (42.9 0.7 in CsA and 47.5 0.91 in
controls).
Chronic CsA administration induced a slight but significant fall
in MAP, which was associated with marked renal vasoconstriction,
demonstrated by a 51.5% decrease in glomerular plasma flow
secondary to a sharp rise in afferent and efferent resistances;
however, since the rise in AR and ER was similar, glomerular
capillary pressure did not change. A considerable reduction in the
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Group
Vehicle
(N = 20)
Cyclosporin(N = 16) P
Body wt g 341.9 8.0 328.9 9.7 NS
Kidney wtg 2.0 0.1 1.7 0.1 <0.005
Htc % 47.5 0.9 42.9 0.7 <0.0005
MAP mm Hg 116.2 2.1 107.8 2.8 <0.01
QA nI/mm 147.5 5.9 71.5 5.8 <0.0005
AR 1010 dyn/second/cm5 2.0 0.1 4.2 0.5 <0.0005
ER 1010 dyn/second/cm5 1.4 0.1 3.2 0.3 <0.0005
SFP mm Hg 32.5 0.6 31.5 0.6 NS
FFP mm Hg 11.2 0.3 11.4 0.4 NS
CP mm Hg 10.9 0.3 10.7 0.9 NS
A mm Hg 18.5 0.4 17.6 0.5 NS
mm Hg 28.4 0.06 27.2 0.08 NS
Poc mm Hg 51.0 0.06 49.0 0.08 NS
K1 ni/second/mm Hg 0.039 0.002 0.021 0.002 <0.0005
SNGFR nI/mm 38.2 1.6 18.0 1.5 <0.0005
GFR mI/mm 1.3 0.1 0.4 0.01 <0.005
SNFF 0.3 0.01 0.3 0.01 NS
TF/P polyfructosan 2.1 0.2 1.7 0.2 <0.025
FPR % 0.5 0.02 0.3 0.05 <0.005
APR nI/mm 18.5 1.3 7.0 1.4 <0.0005
UNV itEq/min 0.3 0.04 0.3 0.13 NS
FENa % 0.2 0.1 0.8 0.3 <0.01
ultrafiltration coefficient, associated with pre- and post-glomeru-
lar vasoconstriction, was observed. The fall in two of the deter-
minants of glomerular filtration rate, that is, 0A and K1, was
responsible for the 53% decrease in SNGFR and 68% decrease in
whole kidney GFR. In addition to glomerular vasoconstriction,
CsA administration inhibited tubular sodium reabsorption. Frac-
tional reabsorption in proximal tubule evaluated by the mean
TF/P polyfructosan ratio was significantly decreased when com-
pared to control. The combination of low fractional reabsorption
and reduced filtered load imposed by the fall in SNGFR resulted
in extremely low values of calculated absolute proximal tubular
reabsorption (APR). Proximal tubular flow rate was also mark-
edly reduced. Urinary sodium excretion (UNaV) was similar to
that found in controls; however, fractional sodium excretion
(FENa) was slightly greater.
No difference was found in the total NO2 /N03 urinary
excretion between V and CsA groups (5.6 1.7 vs. 5.3 2.4
nM/min/g kidney wt), as shown in Figure 1.
Light microscopy analysis showed diffuse isometric vacuoliza-
tion of epithelial proximal cells with numerous inclusion bodies.
Irregularly distributed clarification of some distal tubules and few
foci of basophilic regeneration were also observed. Peritubular
capillaries were dilated and showed some white cells. Scanty and
moderate interstitial edema was seen. Neither glomerular nor
vascular lesions were detected. Electron microscopy observations
confirmed the light microscopy findings.
Effects of the inhibition of NO synthesis
Table 2 and Figure 2 summarize the effect of the inhibition of
NO synthesis. In control rats, NAME increased MAP and pro-
duced renal vasoconstriction, and glomerular plasma flow fell by
28.8% due to a rise in renal vascular resistance; however, a slightly
greater increase in ER than in AR was observed (75 vs. 54.6%).
Intracapillary glomerular pressure rose 16.7% as a result of the
rise in MAP and the predominant efferent constriction. In addi-
tion, the ultrafiltration coefficient decreased 58.8%. These
changes resulted in a 28.9% fall in SNGFR. The inhibition of NO
synthesis also had an effect on tubular sodium reabsorption.
Proximal tubule fractional reabsorption fell slightly, but a con-
comitant reduction in filtered load caused a marked fall in
absolute proximal reabsorption as well as in the absolute amount
delivered by the proximal tubule. Despite these changes, urinary
fractional sodium excretion was increased to 3.5%.
In the CsA group, NAME produced similar changes in MAP as
in the V group. Renal vasoconstriction was pronounced and, in
contrast to controls, a predominance of afferent constriction
occurred: AR rose 90.9% whereas ER rose only 51.4%. The
reduction in glomerular plasma flow was slightly greater than in
controls (37.6 vs. 28.8%) and was associated with a fall in GC
rather than a rise, as observed in controls (—11.6 vs. + 16.7%, P <
0.05). Baseline values of K1 in CsA-treated rats were low com-
pared to V group and were not further reduced by NAME (0.022
to 0.020 nI/second/mm Hg). Reduction of QA and GCproduced
a 39.5% decrease in SNGFR. Similarly to controls, NAME
produced an increase in urinary fractional sodium excretion to
16.5% in spite of the reduction in absolute proximal tubular
reabsorption and distal delivery.
As depicted in Figure 1, NO2/NO3 urinary excretion did not
change during NAME infusion in either group. In control rats 5.6
1.7 vs. 6.2 3.3 nM/min/g kidney wt, and 5.3 2.4 vs. 4.8 2.4
nM/min/g kidney wt in CsA-treated rats.
Effects of the stimulation of NO synthesis
The renal response to L-arginine infusion is depicted on Table
3 and Figure 3. In V group, glomerular hemodynamic response to
L-arginine was the opposite to that observed with NAME. MAP
fell slightly (6.1%), and there was a pronounced vasodilatory
effect. Glomerular plasma flow increased by 72.8% due to a fall in
pre- and post-glomerular resistances of 44.4 and 38.5%, respec-
tively. Since both resistances fell in the same proportion, GC
remained unchanged. K1 values increased 63.2%, which together
with the rise in QA resulted in a 72.6% elevation of SNGFR.
L-arginine infusion also produced opposite effects than NAME on
tubular sodium reabsorption. An increase of 41.8% in proximal
fractional reabsorption associated with an elevated filtered load
resulted in marked enhancement (149%) of absolute proximal
Table 1. Glomerular hemodynamics in cyclosporin nephrotoxicity 5o
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Fig. 1. Urinaiy excretion of N02/N03 in (E) vehicle and () cyclosporin
treated rats in a basal period and during NAME or L-arginine infusion. * p
<0.05 vs. basal period.
Basal NAME Arg
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Table 2. Glomerular hemodynamics before and after NAME infusion
MAP
mm Hg
°A
ni/mm
A E
Poc
mm Hg
K1
ni/second!
mm Hg
SNGFR
ni/mm1010 dyn!second!cm'
V 116.5 —4.5 133.9±9.8 2.2± 0.3 1.6±0.1 51.6±0.7 0.034±0.002 33.9± 2.5
V+NAME 1305±3.6 95.4±6.5 3.4±0.2 2.8±0.2 60.2±1.3 0.015±0.001 24.1±10
P <0.005 <0.01 <0.005 <0.003 <0.003 <0.0005 <0.01
CsA 105.6±1.8 68.6± 10.6 4.4±0.7 3.7±0.7 491±2.0 0.022±0.005 185
CsA + NAME 119.3 3.5 42.8 8,6 8.4 1.3 5.6 1.0 43.4 1.8 0.020 0.006 11.2 2.2
P <0.005 <0.003 <0.005 <0.035 <0.0005 NS <0.003
Table 2. Continued
A E
SNFF
APR
ni/mm
Na
%mm Hg
V 18.8 0.9 29.0 1.4 0.25 0.004 17.6 3.4 0.13 0.02
V + NAME 16.9 1.1 26.0 1.6 0.25 0.005 10.0 1.7 3.50 1.3
P <0.003 <0.003 NS <0.025 <0.025
CsA 17.7 0.9 28.1 1.5 0.27 0.002 9.3 1.8 1.20 0.6
CsA + NAME 17.5 0.8 28.1 1.5 0.27 0.008 5.6 1.0 16.50 5.5
P NS NS NS <0.01 <0.01
MAP AR ER PGC K1 SNGFR
90 *
60 1R
<30 ** II *
Fig. 2. Percent changes in the giomeruiar hemodynamic response to NO
synthesis inhibition with NAME infusion in (E) vehicie and (U) cyciosporin
treated rats. *P < 0.05 vs. basal period; + P < 0.05 vs. percent changes of
vehicle group.
reabsorption. Calculated outflow of the proximal tubule did not
change significantly; however, urinary fractional sodium excretion
increased 19-fold.
In the CsA group, despite chronic renal vasoconstriction,
stimulation of NO synthesis with L-arginine produced similar
changes to those observed in controls. MAP decreased 4.5% and
a marked vasodilatory response was observed. Glomerular plasma
flow increased by 107.1% due to a drastic fall in afferent and
efferent resistances of 55.3 and 51.6%, respectively. P0 remained
unchanged because both resistances fell in the same proportion.
K1 rose to a greater extent than in controls (85.2 vs. 63.2%, P <
0.05), and consequently the increment in SNGFR was greater
than in V rats (114.9 vs. 72.6%, P < 0.05). It is noteworthy,
however, that absolute values of °A and SNGFR during L-
arginine infusion remained lower than in V group. Furthermore,
L-arginine produced a marked increase in both fractional and
absolute proximal tubular reabsorption, although outflow of the
proximal tubule increased and urinary fractional sodium excretion
was increased threefold.
L-arginine infusion produced a significant increase in the total
NO2JNOç urinary excretion in both groups; in V it rose from
5.6 1.7 to 37.6 6.3 nM/min/g kidney wt (P < 0.05) and from
5.3 2.4 to 35.0 8.3 nM/min!g kidney wt in CsA (P <0.05; Fig.
1).
Discussion
We studied the effects of chronic cyclosporin administration in
uninephrectomized rats, a model with functional and hypertro-
phic compensatory changes similar to those observed in renal
transplant recipients [27, 28]. Previous studies in uninephrecto-
mized animals showed a fall in SNGFR due to a reduction in the
ultrafiltration coefficient without changes in resistances or renal
blood flow [27]. In our study, a dose of CsA during 30 days was
sufficient to elevate renal resistances and reduce glomerular
plasma flow. These findings were not associated with vascular
structural changes, suggesting a potentially reversible alteration.
In addition, a significant reduction in ultrafiltration coefficient was
observed; therefore, the fall in two of the GFR determinants
resulted in a 50% decrease in SNGFR. It is recognized that CsA
nephrotoxicity in transplant patients occurs after long treatment
with low doses of the drug [3]; however, in animal models
long-term administration is associated with high mortality. To
avoid this problem our study was performed after 30 days. At this
stage, in addition to renal vasoconstriction tubular toxic effects of
CsA were demonstrated by the presence of vacuolization and
inclusion bodies of the epithelial proximal cells on histological
examination. These alterations were associated with decreased
proximal water and sodium reabsorption, but due to the coexist-
ent reduction in filtered load imposed by the decrease in glomer-
ular filtration rate, urinary sodium excretion did not increase.
The mechanisms involved in CsA-induced vasoconstriction
have not been completely elucidated. It has been demonstrated
that acute administration of the drug stimulates the production of
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Table 3. Glomerular hemodynamics before and after L-arginine infusion
MAP
mm Hg
QA
ni/mm
AR ER p0
mm Hg
K
ni/second/mm Hg
SNGFR
ni/mm1010 dyn/second/cm5
V 119.0± 1.8 155.3 11.1 1.8 1.3±0.1 52.5 1.2 0.038 41.2±3.4
V+ARG 111.7±2.4 268.4±27.7 1.0±0.1 0.8±0.1 55.4±2.0 0.062±0.006 71.1±7.4
P <0.025 <0.0005 <0.0005 <0.0005 NS <0.0025 <0.0005
CsA 115.3 72.2± 13.3 4.7 3.1±0.5 48.9± 1.1 0.027±0.009 18.1±3.5
CsA+ARG 110.1±4.7 149.5 2.1±0.3 1.5 48.2± 1.4 0.050±0.014 38.9±6.8
P NS <0.005 <0.01 <0.01 NS <0.0025 <0.0025
Table 3. Continued
A E
SNFF
APR
ni/mm
FENa
%mm Hg
V 17.9 0.5 28.1 0.8 0.26 0.01 17.1 1.8 0.2 0.1
V + ARG 16.5 0.5 26.1 0.7 0.27 0.01 42.6 15.5 3.8 1.1
P <0.005 <0.005 NS <0.0005 <0.0125
CsA 18.1 0.9 28.1 1.2 0.25 0.02 3.9 5.1 0.9 0.2
CsA + ARG 16.7 0.8 26.2 1.1 0.26 0.01 16.6 5.8 3.0 0.7
P <0.005 <0.025 NS <0.0005 <0.005
120
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Fig. 3. Percent changes in the giomendar hemodynamic response to NO
synthesis stimulation with L-arginine infusion in (D) vehicle and (U)
cyclosponn treated rats. *P < 0.05 vs. basal period; + P < 0.05 vs. percent
changes of vehicle group.
vasoconstrictors such as endothelin, thromboxane A2, and angio-
tensin II [11—17]. These induce contraction of glomerular arte-
rioles and mesangial cells through elevation of cytosolic calcium.
However, the role of the these vasoactive substances in chronic
CsA nephrotoxicity remains to be defined. High plasma levels of
endothelin have been demonstrated during acute infusion of
cyclosporin, but they fall to normal after 60 minutes, and at the
same time endothelin receptor density increases twofold [29];
however, there are no studies in which endothelin was measured
in chronic CsA nephrotoxicity. On the other hand, recent studies
indicate that other vasoconstrictors could contribute to CsA
nephrotoxicity. Benigni et al [17] demonstrated in rats that, after
30 days of CsA administration, urinary excretion of thromboxane
B2 and 2,3-dinor-TxB2 was increased, and also evidenced their
production from isolated perfused kidneys. Furthermore, glomer-
ular production of i-TxB2 in these animals was higher than in
controls. Moreover, activation of the renin-angiotensin system,
demonstrated by elevated plasma renin concentration, increased
cortical content of renin, and higher renin release rate from
cortical kidney slices, has been found in rats treated with CsA for
three weeks [13, 14]. Thus, these pressor systems seem to be at
least partially responsible for the characteristic vasoconstriction
observed in chronic CsA nephrotoxicity.
In cultured endothelial cells, CsA induced early detachment of
the cells, increase in the rate of lysis, cytoplasmic vacuolization,
and decrease in cell replication [30, 31]. In chronic studies, the
drug markedly impaired endothelium dependent vascular smooth
muscle relaxation in aortic rings [32]. These observations suggest
that in vivo chronic CsA administration may result in endothelial
damage and altered production and release of vasorelaxing fac-
tors. Since the contribution of NO in chronic CsA nephrotoxicity
has not been explored, we studied the participation of NO in this
pathophysiological condition.
In our studies, vasoconstriction associated with CsA was not the
result of decreased levels of NO, since urinary excretion of
N027N03 was similar in CsA and V rats. This finding suggests
that NO production might be normal but is insufficient to prevent
the vasoconstriction induced by CsA, and it is possible that
endothelial cells are unable to increase NO production in re-
sponse to stimuli.
When we evaluated the basal production of nitric oxide with the
specific NO synthesis inhibitor (NAME) in vehicle group, a
marked glomerular vasoconstrictive response was observed which
was characterized by predominant efferent constriction, elevation
of glomerular pressure, decrease of K, and marked reduction in
SNGFR, indicating that endothelial NO production is an impor-
tant regulator of glomerular vascular tone. Since Kf is the product
of glomerular permeability and filtration surface area, and this is
determined largely by the tone of mesangial cells, our results
suggest that NO also contributes to maintaining relaxation of
mesangial cells. In this regard, Shultz, Schorer and Raij [33]
recently demonstrated in in vitro preparations that NO produced
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by endothelial cells inhibited angiotensin Il-induced mesangial
cell contraction.
In cyclosporin-treated rats in which renal vessels were chroni-
cally constricted, NAME enhanced renal vasoconstriction even
further. The constrictive effect of NAME predominated in pre-
glonierular vessels inducing a fall in P0 despite the simultaneous
elevation of systemic arterial pressure. However, since no change
was observed in Kf the drop in P0 resulted in a greater reduction
of SNGFR. Lack of effect of NAME on K was probably due to
the fact that the ultrafiltration coefficient was already very low,
since if maximal contraction was achieved by mesangial cells in
response to CsA, no further decrease in filtration area would be
obtained by suppressing NO synthesis. These results suggest that,
in chronic CsA nephrotoxicity, NO synthesis is preserved. This is
further supported by the finding that basal NO21N03 urinary
excretion was similar in V and CsA treated rats. NAME infusion,
however, did not reduce urinary N027N03. Similar findings
have been reported previously [34], and they can be attributed to
the rise in blood pressure and concomitant increase in shear
stress.
Our results with L-arginine further suggest that synthesis is
preserved in chronic CsA nephrotoxicity. This contention was
further supported by N027N03 urinary excretion, which in-
creased up to six times during L-arginine infusion in V and CsA
groups. Stimulation of NO synthesis with L-arginine induced a
marked rise in K, in both control and CsA treated rats, and such
an increment in filtration area can be attributed to mesangial cell
relaxation. In addition, a similar response in both groups indicates
mesangium functional integrity in chronic CsA nephrotoxicity.
Moreover, this finding suggests that NO regulates the tone of
mesangial cells, which is determined by the balance of contracting
and relaxing factors.
Finally, it is known that NAME increases urinary sodium
excretion, and this effect has been attributed to a pressure
natriuresis phenomenon, secondary to the rise in mean arterial
pressure induced by the compound. This notion is supported by
the finding that, when NAME-induced elevation of blood pres-
sure is prevented by intra-arterial administration, a decrease of
sodium reabsorption occurs [35]. In our study NO synthesis
inhibition was associated with an increase in urinary sodium
excretion in control and CsA groups in spite of a marked
reduction in tubule fluid delivery out of the proximal tubule
indicating inhibition of sodium reabsorption in distal segments of
the nephron [9, 191. However, in CsA treated rats, the association
of a further decrease in glomerular filtration rate with an increase
in FENa up to 16% is difficult to explain only by a pressure
natriuresis phenomenon. Such a disproportionate increased so-
dium excretion would indicate a severe renal tubular dysfunction.
In conclusion, our results suggest that renal vasoconstriction
observed in CsA nephrotoxicity is not mediated by NO deficiency.
On the contrary, NO contributes to preserving glomerular circu-
lation by attenuating the effects of vasoconstricting factors asso-
ciated with CsA nephrotoxicity.
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